Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hyperparathyroidism in paraneoplastic hypercalcaemia

M K Drezner, H E Lebovitz

    Lancet (London, England)
    |May 13, 1978
    PubMed
    Summary

    Hypercalcemia in cancer patients is often due to primary hyperparathyroidism, not ectopic hormone production. Measuring nephrogenous cyclic AMP helps identify patients needing further parathyroid evaluation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

    Diabetes, obesity & metabolism·2015
    Same author

    Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
    Same author

    Can vitamin D metabolite measurements facilitate a "treat-to-target" paradigm to guide vitamin D supplementation?

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
    Same author

    Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm.

    Diabetic medicine : a journal of the British Diabetic Association·2013
    Same author

    Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults.

    The Journal of clinical endocrinology and metabolism·2011
    Same author

    New treatments of diabetes: the beta-amylin agonists.

    Annales d'endocrinologie·2008

    Area of Science:

    • Endocrinology
    • Oncology
    • Nephrology

    Background:

    • Hypercalcemia frequently accompanies malignant diseases.
    • Potential causes include parathyroid hormone (PTH) production by tumors, tumor-derived osteolytic factors, or coexisting primary hyperparathyroidism.
    • Differentiating these causes is crucial for appropriate patient management.

    Purpose of the Study:

    • To investigate the mechanisms of hypercalcemia in patients with malignancy.
    • To assess the role of parathyroid hormone function using nephrogenous cyclic AMP (cAMP) levels.
    • To determine the prevalence of coexisting primary hyperparathyroidism in malignancy-associated hypercalcemia.

    Main Methods:

    • Measured urinary nephrogenous cyclic AMP (cAMP) excretion in 15 patients with hypercalcemia and malignancy.
    • Compared cAMP levels to established ranges for normal subjects, primary hyperparathyroidism, and non-malignant hypercalcemia.
    • Utilized surgical neck exploration for patients with elevated cAMP to confirm the source of PTH.

    Main Results:

    • 9 patients (60%) exhibited normal nephrogenous cAMP levels, suggesting non-PTH mediated hypercalcemia.
    • 6 patients (40%) presented with elevated nephrogenous cAMP levels, indicative of increased PTH secretion.
    • Surgical exploration in the elevated cAMP group revealed primary hyperparathyroidism, not ectopic PTH production.

    Conclusions:

    • Coexisting primary hyperparathyroidism is a common, often overlooked cause of hypercalcemia in patients with malignancy.
    • Measurement of nephrogenous cAMP is a valuable tool for identifying patients with malignancy-associated hypercalcemia who are at risk for primary hyperparathyroidism.
    • Early identification of primary hyperparathyroidism allows for targeted treatment and improved patient outcomes.

    Related Experiment Videos